JP2023548745A5 - - Google Patents
Info
- Publication number
- JP2023548745A5 JP2023548745A5 JP2023520066A JP2023520066A JP2023548745A5 JP 2023548745 A5 JP2023548745 A5 JP 2023548745A5 JP 2023520066 A JP2023520066 A JP 2023520066A JP 2023520066 A JP2023520066 A JP 2023520066A JP 2023548745 A5 JP2023548745 A5 JP 2023548745A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cell
- tumor
- approximately
- carcinoma
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063086972P | 2020-10-02 | 2020-10-02 | |
| US63/086,972 | 2020-10-02 | ||
| PCT/US2021/053159 WO2022072820A1 (en) | 2020-10-02 | 2021-10-01 | Lyophilized composition comprising (s)-isopropyl 2-((s)-2- acetamido-3-(1h-indol-3-yl)propanamido)-6-diazo-5- oxohexanoate for subcutaneous administration and the use thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023548745A JP2023548745A (ja) | 2023-11-21 |
| JP2023548745A5 true JP2023548745A5 (https=) | 2024-10-08 |
| JP7846686B2 JP7846686B2 (ja) | 2026-04-15 |
Family
ID=80951026
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023520066A Active JP7846686B2 (ja) | 2020-10-02 | 2021-10-01 | 皮下投与のための（ｓ）－イソプロピル２－（（ｓ）－２－アセトアミド－３－（１ｈ－インドール－３－イル）プロパンアミド）－６－ジアゾ－５－オキソヘキサノエートを含む凍結乾燥組成物およびその使用 |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP4221842A4 (https=) |
| JP (1) | JP7846686B2 (https=) |
| CN (1) | CN116601140A (https=) |
| WO (1) | WO2022072820A1 (https=) |
Family Cites Families (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5093330A (en) | 1987-06-15 | 1992-03-03 | Ciba-Geigy Corporation | Staurosporine derivatives substituted at methylamino nitrogen |
| US6605712B1 (en) | 1990-12-20 | 2003-08-12 | Arch Development Corporation | Gene transcription and ionizing radiation: methods and compositions |
| JP2001523958A (ja) | 1997-03-21 | 2001-11-27 | ブライハム アンド ウィミンズ ホスピタル，インコーポレイテッド | 免疫療法のｃｔｌａ−４結合ペプチド |
| PL354286A1 (en) | 1999-08-23 | 2003-12-29 | Dana-Farber Cancer Institutedana-Farber Cancer Institute | Pd-1, a receptor for b7-4, and uses therefor |
| EP1212422B1 (en) | 1999-08-24 | 2007-02-21 | Medarex, Inc. | Human ctla-4 antibodies and their uses |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| DK2439273T3 (da) | 2005-05-09 | 2019-06-03 | Ono Pharmaceutical Co | Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika |
| BR122017025062B8 (pt) | 2007-06-18 | 2021-07-27 | Merck Sharp & Dohme | anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento |
| AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
| AU2009288730B2 (en) | 2008-08-25 | 2013-06-20 | Amplimmune, Inc. | Compositions of PD-1 antagonists and methods of use |
| US20100069340A1 (en) * | 2008-09-11 | 2010-03-18 | Wyeth | Pharmaceutical compositions of an src kinase inhibitor and an aromatase inhibitor |
| EP3255060A1 (en) | 2008-12-09 | 2017-12-13 | F. Hoffmann-La Roche AG | Anti-pd-l1 antibodies and their use to enhance t-cell function |
| JP4965623B2 (ja) | 2009-09-30 | 2012-07-04 | インターナショナル・ビジネス・マシーンズ・コーポレーション | 所定のソフトウェアの実行パラメータを入力フィールドへ入力することを支援するための方法、システム、およびプログラム |
| US8907053B2 (en) | 2010-06-25 | 2014-12-09 | Aurigene Discovery Technologies Limited | Immunosuppression modulating compounds |
| WO2013006490A2 (en) | 2011-07-01 | 2013-01-10 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to tim3 |
| WO2013043569A1 (en) | 2011-09-20 | 2013-03-28 | Vical Incorporated | Synergistic anti-tumor efficacy using alloantigen combination immunotherapy |
| KR101764096B1 (ko) | 2011-11-28 | 2017-08-02 | 메르크 파텐트 게엠베하 | 항-ｐｄ-ｌ1 항체 및 그의 용도 |
| US8916709B2 (en) * | 2012-03-30 | 2014-12-23 | Cubist Pharmaceuticals, Inc. | 1,2,4-oxadiazole and 1,2,4-thiadiazole β-lactamase inhibitors |
| HK1203971A1 (en) | 2012-05-15 | 2015-11-06 | Bristol-Myers Squibb Company | Cancer immunotherapy by disrupting pd-1/pd-l1 signaling |
| UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
| WO2014022332A1 (en) | 2012-07-31 | 2014-02-06 | The Brigham And Women's Hospital, Inc. | Modulation of the immune response |
| US10344088B2 (en) | 2013-03-15 | 2019-07-09 | Glaxosmithkline Intellectual Property Development Limited | Antigen binding proteins |
| WO2015036499A1 (en) | 2013-09-11 | 2015-03-19 | Medimmune Limited | Anti-b7-h1 antibodies for treating tumors |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| CN108135872A (zh) | 2015-07-31 | 2018-06-08 | 约翰霍普金斯大学 | 用于治疗认知缺陷的谷氨酰胺拮抗剂 |
| EA034571B1 (ru) | 2015-07-31 | 2020-02-21 | Дзе Джонс Хопкинс Юниверсити | Пролекарства аналогов глутамина |
| CN108135875B (zh) * | 2015-07-31 | 2021-12-31 | 约翰霍普金斯大学 | 用于治疗代谢重编程病症的方法和组合物 |
| JP7574198B2 (ja) | 2019-01-18 | 2024-10-28 | ドラセン ファーマシューティカルズ インコーポレイテッド | Ｄｏｎプロドラッグおよび免疫チェックポイント阻害剤による組み合わせ治療法 |
| KR20210151056A (ko) * | 2019-02-11 | 2021-12-13 | 드라센 파마슈티컬스, 인코포레이티드 | L-피로글루탐산으로부터 don 전구약물을 제조하는 방법 |
| JP2022519574A (ja) * | 2019-02-11 | 2022-03-24 | ドラセン ファーマシューティカルズ インコーポレイテッド | Ｌ－グルタミン酸からｄｏｎプロドラッグを調製する方法 |
-
2021
- 2021-10-01 WO PCT/US2021/053159 patent/WO2022072820A1/en not_active Ceased
- 2021-10-01 JP JP2023520066A patent/JP7846686B2/ja active Active
- 2021-10-01 EP EP21876588.1A patent/EP4221842A4/en active Pending
- 2021-10-01 CN CN202180080291.8A patent/CN116601140A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dummer et al. | AZD6244 (ARRY-142886) vs temozolomide in patients with advanced melanoma: an open-label, randomized, multicenter, phase II study | |
| Wang et al. | Camptothesome elicits immunogenic cell death to boost colorectal cancer immune checkpoint blockade | |
| JP2022009707A (ja) | 固形腫瘍治療のための方法 | |
| JP2019509354A5 (https=) | ||
| Satouchi et al. | Efficacy and safety of weekly nab-paclitaxel plus carboplatin in patients with advanced non-small cell lung cancer | |
| JP2015533796A5 (https=) | ||
| IL272697B2 (en) | A polymorphic form of TG02 | |
| Xu et al. | Combined chemo-immuno-photothermal therapy based on ursolic acid/astragaloside IV-loaded hyaluronic acid-modified polydopamine nanomedicine inhibiting the growth and metastasis of non-small cell lung cancer | |
| Yang et al. | A facile boronophenylalanine modified polydopamine dual drug-loaded nanoparticles for enhanced anti-tumor immune response in hepatocellular carcinoma comprehensive treatment | |
| Zhou et al. | Chlorogenic acid sustained-release gel for treatment of glioma and hepatocellular carcinoma | |
| Wang et al. | Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy | |
| CN103533941A (zh) | 治疗恶性实体瘤(包括晚期或转移性恶性实体瘤)的方法 | |
| JP2023548745A5 (https=) | ||
| US20140370129A1 (en) | Dosing regimen and method for treating cancer using a coix seed oil emulsion | |
| Zhu et al. | Histone deacetylase 3 implicated in the pathogenesis of children glioma by promoting glioma cell proliferation and migration | |
| Bai et al. | Mitochondria-targeting nanozyme alleviating temporomandibular joint pain by inhibiting the TNFα/NF-κB/NEAT1 pathway | |
| CN114177299A (zh) | 包含ezh2抑制剂和scd1抑制剂的抗肿瘤药物组合物及其用途 | |
| CN104224750A (zh) | 一种注射用卡巴他赛白蛋白纳米粒制剂及其制备方法 | |
| Xie et al. | Synergistic anticancer effect of rAd/P53 combined with 5-fluorouracil or iodized oil in the early therapeutic response of human colon cancer in vivo | |
| Abbaspour-Ravasjani et al. | Hyaluronic acid-functionalized liposomes for co-delivery of 5-fluorouracil and cannabidiol against colorectal cancer | |
| Hahn et al. | Metronomic oral paclitaxel shows anti-tumor effects in an orthotopic mouse model of ovarian cancer | |
| JP2022507686A5 (https=) | ||
| CN107073015A (zh) | 用于治疗吸烟者中的非小细胞肺癌的维利帕尼与卡铂和紫杉醇的组合 | |
| Bhalla et al. | Phase 1 dose escalation and expansion study of bemcentinib (BGB324), a first-in-class selective AXL inhibitor, with docetaxel in patients with previously treated advanced NSCLC | |
| CN113350281B (zh) | 载药聚合物胶束及其制剂和制备方法 |